S
Scilex Holding Company (SCLX)
NCM – Real vaqt narxi. Valyuta: USD
6.81
-0.09 (-1.30%)
Yopilishda: May 12, 2026, 4:00 PM EDT
6.74
-0.07 (-1.04%)
Bozor oldidan: May 13, 2026, 7:55 AM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
6.81
-0.09 (-1.30%)
Yopilishda: May 12, 2026, 4:00 PM EDT
6.74
-0.07 (-1.04%)
Bozor oldidan: May 13, 2026, 7:55 AM EDT
Scilex Holding Company o'tkir va surunkali og'riqlarni davolash uchun opioid bo'lmagan og'riqni boshqarish mahsulotlarini sotib olish, ishlab chiqish va tijoratlashtirishga qaratilgan. Uning tijoriy mahsulotlari orasida postherpetic nevralgiya (PHN) bilan bog'liq neyropatik og'riqni engillashtirish uchun retsept bo'yicha beriladigan lidokainning topikal mahsuloti bo'lgan ZTlido (lidokainning topikal tizimi) 1,8% (ZTlido), bu postherpetic nerv og'rig'ining bir shaklidir; ELYXYB, kattalardagi aura bilan yoki avrasiz migrenni o'tkir davolash uchun tayyor bo'lgan og'iz orqali yuboriladigan eritma; va GLOPERBA, kattalardagi podagra xurujlarini oldini olish uchun ko'rsatilgan podagradan himoyalovchi dori kolxitsinning suyuq og'iz orqali yuboriladigan shakli. Kompaniya, shuningdek, uchta mahsulot nomzodini ishlab chiqmoqda, shu jumladan SP-102 (10 mg, deksametazon natriy fosfatli yopishqoq jel - SEMDEXA), epidural in'ektsiyalar uchun ishlatiladigan kortikosteroidning yangi yopishqoq jel formulasi, u bel-dumg'aza radikulyar og'rig'ini yoki siyatikani davolash uchun 3-bosqichli tadqiqotni yakunlagan; SP-103 (lidokainning topikal tizimi) 5,4%, surunkali bo'yin og'rig'i va bel og'rig'ini (LBP) davolash uchun ZTlido formulasi, bu 2-bosqichli sinovni yakunlagan; va SP-104 (4,5 mg kam dozali naltrekson gidroxlorid kechiktirilgan chiqariladigan kapsulalari), fibromiyalniy davolash uchun 1-bosqichli sinovlarni yakunlagan kam dozali kechiktirilgan chiqariladigan naltrekson gidroxloridi. U ZTlido va SP-103, shu jumladan lidokainli plastir mahsulotlarini ishlab chiqish uchun Oishi va Itochu bilan, shuningdek, SEMDEXA uchun klinik sinov materiallari ishlab chiqarish va rivojlantirish xizmatlari bo'yicha Lifecore Biomedical, LLC bilan kelishuvga ega. Scilex Holding Company Palo Alto, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Dmitri V. Lissin M.D. | Senior VP of Clinical Development and Medical Affairs & Interim Chief Medical Officer |
| Dr. Henry H. Ji Ph.D. | CEO, President & Executive Chairman |
| Dr. Suketu D. Desai Ph.D. | Interim Chief Technical Officer & Senior VP |
| Mr. Stephen Ma | Senior VP, CFO, COO, Corporate Secretary & Director |
| Mr. Suresh K. Khemani | Senior VP, Chief Commercial Officer & GM of Scilex Pharma |
| Ms. Gigi DeGuzman | VP & Chief People Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-05 | DEFA14A | d298016ddefa14a.htm |
| 2026-04-30 | DEF 14A | d146109ddef14a.htm |
| 2026-04-28 | 8-K | sclx-20260426.htm |
| 2026-04-16 | S-3 | d897596ds3.htm |
| 2026-04-10 | 10-K | sclx-20251231.htm |
| 2026-04-01 | NT 10-K | scilex_nt_10k_2025.htm |
| 2026-03-13 | 8-K | sclx-20260313.htm |
| 2026-02-20 | 8-K | sclx-20260219.htm |
| 2026-02-13 | DRS | filename1.htm |
| 2026-02-09 | S-8 | d28614ds8.htm |